Please use this identifier to cite or link to this item:
https://hdl.handle.net/2445/183777
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chen, Baixin | - |
dc.contributor.author | Guo, Miaolan | - |
dc.contributor.author | Peker, Yüksel | - |
dc.contributor.author | Salord, Neus | - |
dc.contributor.author | Drager, Luciano F. | - |
dc.contributor.author | Lorenzi-Filho, Geraldo | - |
dc.contributor.author | Tang, Xiangdong | - |
dc.contributor.author | Li, Yun | - |
dc.date.accessioned | 2022-03-04T11:38:27Z | - |
dc.date.available | 2022-03-04T11:38:27Z | - |
dc.date.issued | 2022-01-25 | - |
dc.identifier.issn | 2077-0383 | - |
dc.identifier.uri | https://hdl.handle.net/2445/183777 | - |
dc.description.abstract | Background: Obstructive sleep apnea (OSA) is associated with dyslipidemia. However, the effects of continuous positive airway pressure (CPAP) treatment on lipid profiles are unclear. Methods: PubMed/Medline, Embase and Cochrane were searched up to July 2021. Randomized controlled trials (RCTs) of CPAP versus controls with >= 4 weeks treatment and reported pre- and post-intervention lipid profiles were included. Weighted mean difference (WMD) was used to assess the effect size. Meta-regression was used to explore the potential moderators of post-CPAP treatment changes in lipid profiles. Results: A total of 14 RCTs with 1792 subjects were included. CPAP treatment was associated with a significant decrease in total cholesterol compared to controls (WMD = -0.098 mmol/L, 95% CI = -0.169 to -0.027, p = 0.007, I-2 = 0.0%). No significant changes in triglyceride, high-density lipoprotein nor low-density lipoprotein were observed after CPAP treatment (all p > 0.2). Furthermore, meta-regression models showed that age, gender, body mass index, daytime sleepiness, OSA severity, follow-up study duration, CPAP compliance nor patients with cardiometabolic disease did not moderate the effects of CPAP treatment on lipid profiles (all p > 0.05). Conclusions: CPAP treatment decreases total cholesterol at a small magnitude but has no effect on other markers of dyslipidemia in OSA patients. Future studies of CPAP therapy should target combined treatment strategies with lifestyle modifications and/or anti-hyperlipidemic medications in the primary as well as secondary cardiovascular prevention models. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI AG | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/jcm11030596 | - |
dc.relation.ispartof | Journal of Clinical Medicine, 2022, vol 11, num 3 | - |
dc.relation.uri | https://doi.org/10.3390/jcm11030596 | - |
dc.rights | cc by (c) Chen, Baixin et al, 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Síndromes d'apnea del son | - |
dc.subject.classification | Trastorns del metabolisme dels lípids | - |
dc.subject.other | Sleep apnea syndromes | - |
dc.subject.other | Lipid metabolism disorders | - |
dc.title | Effect of Continuous Positive Airway Pressure on Lipid Profiles in Obstructive Sleep Apnea: A Meta-Analysis | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2022-03-03T11:51:04Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 35160050 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
jcm-11-00596-v2.pdf | 743.08 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License